Correction of a pathogenic gene mutation in human embryos

  • Nature volume 548, pages 413419 (24 August 2017)
  • doi:10.1038/nature23305
  • Download Citation


Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR–Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.

  • Subscribe to Nature for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Change history

  • Updated online 02 October 2017

    Editorial Note: Readers are alerted that some of the conclusions of this paper are subject to critiques that are being considered by editors. Some of these critiques have been publicly deposited in preprint form. A further editorial response will follow the resolution of these issues.


  1. 1.

    et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003)

  2. 2.

    , , & Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene 573, 188–197 (2015)

  3. 3.

    et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat. Genet. 41, 187–191 (2009)

  4. 4.

    et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336, 1401–1408 (1997)

  5. 5.

    et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 92, 785–789 (1995)

  6. 6.

    , & Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J. Mol. Cell. Cardiol. 50, 613–620 (2011)

  7. 7.

    , & Development and applications of CRISPR–Cas9 for genome engineering. Cell 157, 1262–1278 (2014)

  8. 8.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013)

  9. 9.

    , , , & Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019 (2014)

  10. 10.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013)

  11. 11.

    , , & Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3, e04766 (2014)

  12. 12.

    et al. Correction of a genetic disease in mouse via use of CRISPR–Cas9. Cell Stem Cell 13, 659–662 (2013)

  13. 13.

    & Targeted genome editing in primate embryos. Cell Res. 25, 767–768 (2015)

  14. 14.

    et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918 (2013)

  15. 15.

    et al. Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. Cell Stem Cell 18, 625–636 (2016)

  16. 16.

    , , & Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013)

  17. 17.

    & A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15, 321–334 (2014)

  18. 18.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012)

  19. 19.

    et al. Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. Genome Biol. 16, 87 (2015)

  20. 20.

    , , & The timing of pronuclear formation, DNA synthesis and cleavage in the human 1-cell embryo. Mol. Hum. Reprod. 2, 299–306 (1996)

  21. 21.

    , & Asymmetric parental genome engineering by Cas9 during mouse meiotic exit. Sci. Rep. 4, 7621 (2014)

  22. 22.

    et al. High-frequency off-target mutagenesis induced by CRISPR–Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013)

  23. 23.

    et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013)

  24. 24.

    et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132–141 (2014)

  25. 25.

    et al. Digenome-seq: genome-wide profiling of CRISPR–Cas9 off-target effects in human cells. Nat. Methods 12, 237–243 (2015)

  26. 26.

    , , , & Genome-wide target specificities of CRISPR–Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res. 26, 406–415 (2016)

  27. 27.

    et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011)

  28. 28.

    & Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 18, 6097–6100 (1990)

  29. 29.

    , & BatMis: a fast algorithm for k-mismatch mapping. Bioinformatics 28, 2122–2128 (2012)

  30. 30.

    , , , & Enhancing homology-directed genome editing by catalytically active and inactive CRISPR–Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34, 339–344 (2016)

  31. 31.

    & The new frontier of genome engineering with CRISPR–Cas9. Science 346, 1258096 (2014)

  32. 32.

    et al. Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling. PLoS Genet. 10, e1004471 (2014)

  33. 33.

    et al. The landscape of mouse meiotic double-strand break formation, processing, and repair. Cell 167, 695–708 (2016)

  34. 34.

    et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci. Transl. Med. 5, 172ra21 (2013)

  35. 35.

    et al. CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. Mol. Genet. Genomics 292, 525–533 (2017)

  36. 36.

    et al. Increasing the efficiency of homology-directed repair for CRISPR–Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543–548 (2015)

  37. 37.

    et al. Increasing the efficiency of precise genome editing with CRISPR–Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538–542 (2015)

  38. 38.

    et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156, 836–843 (2014)

  39. 39.

    et al. CRISPR/Cas9-mediated Dax1 knockout in the monkey recapitulates human AHC-HH. Hum. Mol. Genet. 24, 7255–7264 (2015)

  40. 40.

    et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6, 363–372 (2015)

  41. 41.

    et al. Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos. Sci. Rep. 7, 42081 (2017)

  42. 42.

    , & Electroporation of Cas9 protein/sgRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse. Dev. Biol. 418, 1–9 (2016)

  43. 43.

    et al. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344, 189–193 (2014)

  44. 44.

    et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 493, 627–631 (2013)

  45. 45.

    , , & Genotyping with CRISPR–Cas-derived RNA-guided endonucleases. Nat. Commun. 5, 3157 (2014)

  46. 46.

    , & Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014)

  47. 47.

    , , & Cas-analyzer: an online tool for assessing genome editing results using NGS data. Bioinformatics 33, 286–288 (2017)

  48. 48.

    et al. Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. Bioinformatics 29, 2041–2043 (2013)

Download references


We acknowledge the OHSU Institutional Review Board (IRB), Innovative Research Advisory Panel (IRAP), Scientific Review Committee (SRC) and Data Safety Monitoring Committee (DSMC) for oversight and guidance on this study. We thank all study participants for tissue donations; the Women’s Health Research Unit staff, IVF laboratory staff, University Fertility Consultants and the Reproductive Endocrinology and Infertility Division in the Department of Obstetrics and Gynecology, OHSU for support and procurement of human gametes; S. Olson and Research Cytogenetics Laboratory at OHSU for cytogenetic analysis of ES cells; S. Cooper from the Wallace Division of Smiths Medical for donating ICSI and gamete manipulation micropipettes; Y. Wang, T. Wu and Y. Shen from BGI-Shenzhen for help with sample preparation, sequencing and data analyses; M. Ku from the H. A. and Mary K. Chapman Charitable Foundations Genomic Sequencing Core of the Salk Institute for next generation sequencing; and E. Aizawa and R. Hernandez-Benitez from the laboratory of JCIB for assistance. Studies conducted at OHSU were supported by OHSU institutional funds. Work in the laboratory of J.-S.K. was supported by the Institute for Basic Science (IBS-R021-D1). Work in the laboratory of J.C.I.B. was supported by the G. Harold and Leila Y. Mathers Charitable Foundation, the Moxie Foundation and the Leona M. and Harry B. Helmsley Charitable Trust. Work at BGI was supported by the Shenzhen Municipal Government of China (DRC-SZ [2016] 884).

Author information

Author notes

    • Hong Ma
    • , Nuria Marti-Gutierrez
    • , Sang-Wook Park
    •  & Jun Wu

    These authors contributed equally to this work.

    • Juan Carlos Izpisua Belmonte
    • , Paula Amato
    • , Jin-Soo Kim
    • , Sanjiv Kaul
    •  & Shoukhrat Mitalipov

    These authors jointly supervised this work.


  1. Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, 3303 Southwest, Bond Avenue, Portland, Oregon 97239, USA

    • Hong Ma
    • , Nuria Marti-Gutierrez
    • , Yeonmi Lee
    • , Amy Koski
    • , Dongmei Ji
    • , Tomonari Hayama
    • , Riffat Ahmed
    • , Hayley Darby
    • , Crystal Van Dyken
    • , Ying Li
    • , Eunju Kang
    • , David Battaglia
    • , Don P. Wolf
    • , Paula Amato
    •  & Shoukhrat Mitalipov
  2. Center for Genome Engineering, Institute for Basic Science, 70, Yuseong-daero 1689-gil, Yuseong-gu, Daejeon, 34047, Republic of Korea

    • Sang-Wook Park
    • , A.-Reum Park
    • , Sang-Tae Kim
    •  & Jin-Soo Kim
  3. Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA

    • Jun Wu
    • , Keiichiro Suzuki
    •  & Juan Carlos Izpisua Belmonte
  4. Department of Chemistry, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul, 151-747, Republic of Korea

    • Daesik Kim
    •  & Jin-Soo Kim
  5. BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China

    • Jianhui Gong
    • , Ying Gu
    •  & Xun Xu
  6. China National GeneBank, BGI-Shenzhen, Jinsha Road, Dapeng District, Shenzhen, 518210, China

    • Jianhui Gong
    • , Ying Gu
    •  & Xun Xu
  7. BGI-Qingdao, 2877 Tuanjie Road, Sino-German Ecopark, Qingdao, 266000, China

    • Jianhui Gong
    • , Ying Gu
    •  & Xun Xu
  8. Shenzhen Engineering Laboratory for Innovative Molecular Diagnostics, BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China

    • Jianhui Gong
  9. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Oregon Health & Science University, 3303 Southwest, Bond Avenue, Portland, Oregon 97239, USA

    • David Battaglia
    • , Sacha A. Krieg
    • , David M. Lee
    • , Diana H. Wu
    •  & Paula Amato
  10. Knight Cardiovascular Institute, Oregon Health & Science University, 3181 Southwest, Sam Jackson Park Road, Portland, Oregon 97239, USA

    • Stephen B. Heitner
    • , Sanjiv Kaul
    •  & Shoukhrat Mitalipov


  1. Search for Hong Ma in:

  2. Search for Nuria Marti-Gutierrez in:

  3. Search for Sang-Wook Park in:

  4. Search for Jun Wu in:

  5. Search for Yeonmi Lee in:

  6. Search for Keiichiro Suzuki in:

  7. Search for Amy Koski in:

  8. Search for Dongmei Ji in:

  9. Search for Tomonari Hayama in:

  10. Search for Riffat Ahmed in:

  11. Search for Hayley Darby in:

  12. Search for Crystal Van Dyken in:

  13. Search for Ying Li in:

  14. Search for Eunju Kang in:

  15. Search for A.-Reum Park in:

  16. Search for Daesik Kim in:

  17. Search for Sang-Tae Kim in:

  18. Search for Jianhui Gong in:

  19. Search for Ying Gu in:

  20. Search for Xun Xu in:

  21. Search for David Battaglia in:

  22. Search for Sacha A. Krieg in:

  23. Search for David M. Lee in:

  24. Search for Diana H. Wu in:

  25. Search for Don P. Wolf in:

  26. Search for Stephen B. Heitner in:

  27. Search for Juan Carlos Izpisua Belmonte in:

  28. Search for Paula Amato in:

  29. Search for Jin-Soo Kim in:

  30. Search for Sanjiv Kaul in:

  31. Search for Shoukhrat Mitalipov in:


S.M., S.K., Y.Le., N.M.-G. and H.M. conceived the study and designed the experiments. S.-W.P., J.-S.K. and K.S. designed CRISPR–Cas9 constructs. A.K., S.B.H. and S.K. coordinated recruitment of gamete donors. Y.Le. and R.A. derived patient iPSCs and S.-W.P., J.W.,.K.S and J.C.I.B. tested the specificity of the CRISPR–Cas9 systems in patient iPSCs. P.A., D.B., D.M.L., S.A.K. and D.H.W. conducted ovarian stimulation and oocyte retrieval. N.M.-G., Y.Le., D.J. and T.H. performed CRISPR–Cas9 injections, fertilizations, embryo culture and blastomere isolation experiments. N.M.-G., D.J., H.D., C.V.D., Y.Li and E.K. performed DNA extraction, PCR and Sanger sequencing. S.-W.P., A.-R.P., D.K., S.-T.K. and J.-S.K. performed Digenome-seq, WGS and analyses and independently corroborated embryo on-target editing by deep sequencing. J.G., Y.G., X.X. and J.W. performed whole-exome sequencing and analyses. H.M., N.M.-G., S.-W.P., J.W., A.K., D.P.W., S.B.H., J.C.I.B., P.A., J.-S.K., S.K. and S.M. analysed the data and wrote the manuscript.

Competing interests

J.-S.K. is a co-founder and shareholder of ToolGen, Inc, and S.M. is a co-founder and shareholder of Mitogenome Therapeutics, Inc and Health and Science Center “M1” Inc and declare competing financial interests. The other authors declare no competing financial interests.

Corresponding authors

Correspondence to Juan Carlos Izpisua Belmonte or Paula Amato or Jin-Soo Kim or Sanjiv Kaul or Shoukhrat Mitalipov.

Reviewer Information Nature thanks F. Lanner and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Reporting summary

Excel files

  1. 1.

    Supplementary Table 1

    Genotypes of individual iPSC clones

  2. 2.

    Supplementary Table 2

    Genotypes of individual blastomeres in control embryos

  3. 3.

    Supplementary Table 3

    Genotypes of individual blastomeres in zygote injected embryos

  4. 4.

    Supplementary Table 4

    Genotypes of individual blastomeres in M-phase injected embryos

  5. 5.

    Supplementary Table 5

    Mutagenic indel frequencies at potential off-target sites captured by Digenome-sequencing

  6. 6.

    Supplementary Table 6

    Whole exome sequencing (WES) analyses of variants identified using Hg19 as reference genome

  7. 7.

    Supplementary Table 7

    List of predicted off-target sites

  8. 8.

    Supplementary Table 8

    WES analyses of non-inherited variants


  1. 1.

    Video: CRISPR/Cas9 injection into human oocytes and zygotes

    CRISPR/Cas9 injection into human oocytes and zygotes. S-phase CRISPR/Cas9 injection was performed 18 hours after ICSI. M-phase injections were co-injected with sperm during ICSI.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.